An Unusual Case of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

IF 0.7 Q4 HEMATOLOGY
Case Reports in Hematology Pub Date : 2022-06-09 eCollection Date: 2022-01-01 DOI:10.1155/2022/4700787
Sarah Premji, Andreia Barbieri, Christine Roth, Eric M Rohren, Gustavo Rivero, Sravanti P Teegavarapu
{"title":"An Unusual Case of Breast Implant-Associated Anaplastic Large Cell Lymphoma.","authors":"Sarah Premji,&nbsp;Andreia Barbieri,&nbsp;Christine Roth,&nbsp;Eric M Rohren,&nbsp;Gustavo Rivero,&nbsp;Sravanti P Teegavarapu","doi":"10.1155/2022/4700787","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare disease entity associated with textured breast implants. Though the clinical course is typically indolent, BIA-ALCL can occasionally invade through the capsule into the breast parenchyma with spread to the regional lymph nodes and beyond including chest wall invasive disease.</p><p><strong>Case: </strong>We present the case of a 51-year-old female with a history of bilateral silicone breast implants placed approximately twenty years ago who presented with two months of progressively enlarging right breast mass. Ultrasound-guided biopsy of right breast mass and right axillary lymph node showed CD 30-positive <i>ALK</i>-negative anaplastic large cell lymphoma, and staging work up showed extension of the tumor to chest wall and ribs consistent with advanced disease. She received CHP-BV (cyclophosphamide, doxorubicin, prednisone, and brentuximab vedotin) for six cycles with complete metabolic response. This was followed by extensive surgical extirpation and reconstruction, radiation for residual disease and consolidation with autologous stem cell transplant. She is currently on maintenance brentuximab vedotin with no evidence of active disease post autologous stem cell transplant.</p><p><strong>Conclusion: </strong>Treatment guidelines for advanced chest wall invasive BIA-ALCL are not well defined. Lack of predictive factors warrants mutation analysis and genetic sequencing to identify those at highest risk of progression to chest wall invasive disease. This rare case highlights the need for definitive consensus on the optimal management of chest wall invasive BIA-ALCL.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203203/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/4700787","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare disease entity associated with textured breast implants. Though the clinical course is typically indolent, BIA-ALCL can occasionally invade through the capsule into the breast parenchyma with spread to the regional lymph nodes and beyond including chest wall invasive disease.

Case: We present the case of a 51-year-old female with a history of bilateral silicone breast implants placed approximately twenty years ago who presented with two months of progressively enlarging right breast mass. Ultrasound-guided biopsy of right breast mass and right axillary lymph node showed CD 30-positive ALK-negative anaplastic large cell lymphoma, and staging work up showed extension of the tumor to chest wall and ribs consistent with advanced disease. She received CHP-BV (cyclophosphamide, doxorubicin, prednisone, and brentuximab vedotin) for six cycles with complete metabolic response. This was followed by extensive surgical extirpation and reconstruction, radiation for residual disease and consolidation with autologous stem cell transplant. She is currently on maintenance brentuximab vedotin with no evidence of active disease post autologous stem cell transplant.

Conclusion: Treatment guidelines for advanced chest wall invasive BIA-ALCL are not well defined. Lack of predictive factors warrants mutation analysis and genetic sequencing to identify those at highest risk of progression to chest wall invasive disease. This rare case highlights the need for definitive consensus on the optimal management of chest wall invasive BIA-ALCL.

Abstract Image

Abstract Image

乳房假体相关间变性大细胞淋巴瘤1例。
简介:乳房植入物相关间变性大细胞淋巴瘤(BIA-ALCL)是一种罕见的与有纹理的乳房植入物相关的疾病。虽然临床过程通常是惰性的,但BIA-ALCL偶尔可以通过被膜侵入乳腺实质并扩散到区域淋巴结并超越胸壁侵袭性疾病。病例:我们提出的情况下,51岁的女性与双侧硅胶乳房植入史放置大约20年前,谁提出了两个月的逐步扩大的右乳房肿块。超声引导下右乳腺肿块及右腋窝淋巴结活检显示cd30阳性alk阴性间变性大细胞淋巴瘤,分期显示肿瘤向胸壁和肋骨延伸,符合疾病晚期。她接受了CHP-BV(环磷酰胺、阿霉素、强的松和布伦妥昔单抗韦多汀)治疗6个周期,代谢完全缓解。随后是广泛的手术切除和重建,放射治疗残余疾病和自体干细胞移植巩固。她目前正在接受布伦妥昔单抗维多汀维持治疗,自体干细胞移植后无活动性疾病迹象。结论:晚期胸壁浸润性BIA-ALCL的治疗指南尚不明确。由于缺乏预测因素,需要进行突变分析和基因测序,以确定进展为胸壁侵袭性疾病的最高风险。这个罕见的病例强调了对胸壁浸润性BIA-ALCL的最佳治疗需要明确的共识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
51
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信